Impact of T-cell costimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis: A clinical and imaging study of abatacept (the ADJUST trial)

Annals of the Rheumatic Diseases

Volumn 69, Issue 3, 2010, Pages 510-516

  Emery, P ^a   Durez, P ^b   Dougados, M ^c   Legerton, C W ^d   Becker, J C ^e   Vratsanos, G ^e   Genant, H K ^f,g   Peterfy, C ^g   Mitra, P ^e   Overfield, S ^e   Qi, K ^e   Westhovens, R ^h  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^c Descartes University ^*  (France)

^d Low Country Family Podiatry   (United States)

^e BRISTOL MYERS SQUIBB   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g SYNARC INC   (United States)

^h UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PREDNISONE; RHEUMATOID FACTOR;

ADULT; ARTHRITIS; ARTICLE; CELL STIMULATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE ACTIVITY; DISEASE DURATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; FEMALE; GASTROENTERITIS; HUMAN; INJECTION SITE REACTION; LOW DRUG DOSE; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEITIS; PATIENT ATTITUDE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; SCORING SYSTEM; SORE THROAT; SYNOVITIS; T LYMPHOCYTE; UNDIFFERENTIATED ARTHRITIS; URINARY TRACT INFECTION;

ADULT; ANTIRHEUMATIC AGENTS; ARTHRITIS; AUTOANTIBODIES; BIOLOGICAL MARKERS; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; IMMUNITY, CELLULAR; IMMUNOCONJUGATES; IMMUNOSUPPRESSIVE AGENTS; MALE; PEPTIDES, CYCLIC; RHEUMATOID FACTOR; SYNOVITIS; T-LYMPHOCYTES;

EID: 77949442819     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2009.119016     Document Type: Article

References (27)

1. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 2008;58(Suppl):S126- 35.
2. Emery P, Breedveld FC, Hall S, et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet 2008;372:375-82.
3. Grigor C, Capell H, Stirling A, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 2004;364:263- 9.
4. van der Helm-van Mil AH, Verpoort KN, Breedveld FC, et al. The HLA-DRB1 shared epitope alleles are primarily a risk factor for anti-cyclic citrullinated peptide antibodies and are not an independent risk factor for development of rheumatoid arthritis. Arthritis Rheum 2006;54:1117- 21.
5. Huizinga TW, Amos CI, van der Helm-van Mil AH, et al. Refining the complex rheumatoid arthritis phenotype based on specificity of the HLA-DRB1 shared epitope for antibodies to citrullinated proteins. Arthritis Rheum 2005;52:3433-8.
6. van Dongen H, van Aken J, Lard LR, et al. Efficacy of methotrexate treatment in patients with probable rheumatoid arthritis: a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2007;56:1424-32.
7. Saleem B, Mackie S, Quinn M, et al. Does the use of TNF antagonist therapy in poor prognosis, undifferentiated arthritis prevent progression to rheumatoid arthritis? Ann Rheum Dis 2008;67:1178- 80.
8. Janossy G, Panayi G, Duke O, et al. Rheumatoid arthritis: a disease of T-lymphocyte/ macrophage immunoregulation. Lancet 1981;2:839-42.
9. van Boxel JA, Paget SA. Predominantly T-cell infiltrate in rheumatoid synovial membranes. N Engl J Med 1975;293:517-20.
10. Mima T, Saeki Y, Ohshima S, et al. Transfer of rheumatoid arthritis into severe combined immunodeficient mice. The pathogenetic implications of T cell populations oligoclonally expanding in the rheumatoid joints. J Clin Invest 1995;96:1746-58.
11. Sakata A, Sakata K, Ping H, et al. Successful induction of severe destructive arthritis by the transfer of in vitro-activated synovial fluid T cells from patients with rheumatoid arthritis (RA) in severe combined immunodeficient (SCID) mice. Clin Exp Immunol 1996;104:247-54.
12. Raza K, Falciani F, Curnow SJ, et al. Early rheumatoid arthritis is characterized by a distinct and transient synovial fluid cytokine profile of T cell and stromal cell origin. Arthritis Res Ther 2005;7:R784-95.
13. Chambers CA, Kuhns MS, Allison JP. Cytotoxic T lymphocyte antigen-4 (CTLA-4) regulates primary and secondary peptide-specific CD4(+) T cell responses. Proc Natl Acad Sci USA 1999;96:8603-8.
14. Kliwinski C, Kukral D, Postelnek J, et al. Prophylactic administration of abatacept prevents disease and bone destruction in a rat model of collagen-induced arthritis. J Autoimmun 2005;25:165-71.
15. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
16. Clinicaltrials.gov. Study of abatacept versus placebo to assess the prevention of rheumatoid arthritis (RA) in adult patients. http:// clinicaltrials.gov/ct2/show/NCT00124449?term=abatacept&recr=closed&cond= undifferentiated+arthritis&rank=1 (accessed November 2009).
17. Genant HK. Methods of assessing radiographic change in rheumatoid arthritis. Am J Med 1983;75:35-47.
18. Genant HK, Peterfy CG, Westhovens R, et al. Abatacept inhibits progression of structural damage in rheumatoid arthritis: results from the long-term extension of the AIM trial. Ann Rheum Dis 2008;67:1084-9.
19. Ostergaard M, Peterfy C, Conaghan P, et al. OMERACT rheumatoid arthritis magnetic resonance imaging studies. Core set of MRI acquisitions, joint pathology definitions, and the OMERACT RA-MRI scoring system. J Rheumatol 2003;30:1385-6.
20. Anonymous. StatXact (Cytel). Available at http://www.cytel.com/products/statxact/StatXact-brochure.pdf and http://www.cytel.com/products/statxact/ (accessed November 2009).
21. Cuchacovich M, Catalan D, Wainstein E, et al. Basal anti-cyclic citrullinated peptide (anti-CCP) antibody levels and a decrease in anti-CCP titres are associated with clinical response to adalimumab in rheumatoid arthritis. Clin Exp Rheumatol 2008;26:1067-73.
22. Alessandri C, Bombardieri M, Papa N, et al. Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following anti-TNFalpha therapy (infliximab) in rheumatoid arthritis is associated with clinical improvement. Ann Rheum Dis 2004;63:1218-21.
23. Hetland ML, Ejbjerg B, Horslev-Petersen K, et al. MRI bone oedema is the strongest predictor of subsequent radiographic progression in early rheumatoid arthritis. Results from a 2-year randomised controlled trial (CIMESTRA). Ann Rheum Dis 2009;68:384-90.
24. Buch MH, Boyle DL, Rosengren S, et al. Mode of action of abatacept in rheumatoid arthritis patients having failed tumour necrosis factor blockade: a histological, gene expression and dynamic magnetic resonance imaging pilot study. Ann Rheum Dis 2009;68:1220-7.
25. Axmann R, Herman S, Zaiss M, et al. CTLA-4 directly inhibits osteoclast formation. Ann Rheum Dis 2008;67:1603-9.
26. Wells G, Becker JC, Teng J, et al. Validation of the Disease Activity Score 28 (DAS28) and EULAR response criteria based on CRP against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on ESR. Ann Rheum Dis 2009;68:954-60.
27. Harrison BJ, Symmons DP, Barrett EM, et al. The performance of the 1987 ARA classification criteria for rheumatoid arthritis in a population based cohort of patients with early inflammatory polyarthritis. American Rheumatism Association. J Rheumatol 1998;25:2324-30.